CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D013651: Taste Disorders NIH

(Synonyms: Taste Disorders)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug1257 Investigation of smell and taste disorders Wiki 0.71

Correlated MeSH Terms (0)


Name (Synonyms) Correlation

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials


1 Prevalence and Clinical Evolution of Olfactory and Taste Disorders in Patients Infected by SARS-CoV-2

A novel coronavirus SARS-CoV-2 HAS arose in 2019 in Wuhan, China. Beside the classical semiology of this infection, numerous patients described olfactory and teste disorders. These symptoms are not described in this coronavirus, neurotropism of coronaviridae has been documented before. The aim of the study is to evaluate prevalence of anosmia and dysgeusia (olfactory and taste disorders) in coronavirus diagnosed patients and compare with different clinical conditions. The second endpoint is to evaluate the duration of these symptoms in order to better understand the semiology of this infection.

NCT04361565 COVID-19 by SARS-CoV-2 Infection
MeSH:Taste Disorders

Primary Outcomes

Description: Prevalence for anosmia in the COVID-19 + patients

Measure: Anosmia

Time: 45 days

Description: Prevalence for ageusia in the COVID-19 + patients

Measure: Ageusia

Time: 45 days

Description: Duration measured in days

Measure: Duration of the loss of anosmia ageusia

Time: 45 days

2 Smell and Taste Disorders in COVID-19 Patients: Prospective Observational Study

This is a prospective monocentric observational study with the aim of investigating the demographic and clinical factors related to the smell and taste disorders in patients with Severe Acute Respiratory Syndrome - Coronavirus - 2 (Sars-Cov-2) infection.

NCT04427332 covid19 Other: Investigation of smell and taste disorders
MeSH:Taste Disorders

Primary Outcomes

Description: Identify the demographic and clinical factors related to the sense of smell and taste in patients with Sars-CoV-2 infection included in the study.

Measure: Identification of demographic and clinical factors in covid19 patients.

Time: Until patient discharge from the hospital (approximately four months)

Secondary Outcomes

Description: Description in patients with Sars-CoV-2 infection the evolution of the symptoms (disturbances of smell and taste) understood as partial or total regression by 1-month and 3-month follow-up

Measure: Description of the disturbances of smell and taste

Time: Until patient discharge from the hospital (approximately four months)

Description: Define which factors (demographic and clinical) influence the improvement of the sense of smell and taste

Measure: Description of factors that influence smell and taste

Time: Until patient discharge from the hospital (approximately four months).


HPO Nodes